Associated Papers
Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors.
Burr R et al.
Nature Cancer, 2024
39406916 (PubMed )
Supplement: 43018_2024_840_MOESM2_ESM.xlsx › Supplementary_Table_5
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
36830579 (PubMed )
Supplement: biomolecules-13-00210-s001.zip › biomolecules-2098784-supplementary.xlsx › Table_S2
Molecular Genetic Profile of 300 Japanese Patients with Diffuse Gliomas Using a Glioma-tailored Gene Panel.
Higa N et al.
Neurologia Medico-chirurgica, 2022
36031351 (PubMed )
Supplement: 1349-8029-62-0391-s005.pdf
Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review.
Wang Q et al.
Frontiers in Oncology, 2022
A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer Database.
Pappula AL et al.
Cancers, 2021
34503108 (PubMed )
Supplement: cancers-13-04299-s001.zip › Supplemental_Tables_final.xlsx › Table_S11
The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive.
Yu S et al.
Oncotargets and Therapy, 2017
Select a paper to view details